Leukotrienes A4 and B4 stimulate the formation of cyclic amp in human leukocytes  by Claesson, Hans-Erik
Volume 139, number 2 FEBS LETTERS March 1982 
LEUKOTRIENES & AND B4 STIMULATE THE FORMATION OF CYCLIC AMP IN 
HUMAN LEUKOCYTES 
Hans-Erik CLAESSON 
Department of PhysiologicaI Chemistry, Karolinska Institutet, S-104 01 Stockholm, Sweden 
Received 8February 1982 
1. Introduction 
Recent studies of arachidonic acid metabolism in 
polymorphonuclear leukocytes (PMNL) have led to 
the discovery of leukotrienes [l] (fig.1). These com- 
pounds have a wide spectrum of biological effects. 
The activity of most preparations of slow reacting 
substance of anaphylaxis (SRS-A) is due to leukotriene 
(LT) C4 and its metabolites LTD4 and LTE4 [ 11. LTB4 
induces release of lysosomal enzymes [2,3] and is a 
potent chemotactic compound [4,5]. The signal for 
activation of these processes is unknown. 
Roche (Basel); Dextran T-500 from Pharmacia Fine 
Chemicals (Uppsala) and Hypaque/Ficoll from 
Nyegaard and Co. (Oslo). 
2.1. Separation of leukocytes 
Inflammatory active agents such as latex particles 
[6],N-formyl-methionyl-leucyl-phenylalanine [7,8], 
C5a [7], calcium ionophore A23187 [8], immune 
complex [8], zymosan-treated serum [S] and opsinized 
zymosan [9] have been shown to cause a small rise in 
cyclic AMP levels, indicating a relationship between 
neutrophil activation and this cyclic nucleotide. There- 
fore, we investigated the effects of various leukotrienes 
on cyclic AMP formation in human PMNL. 
PMNL were either isolated as in [lo] or in the fol- 
lowing way: Blood from healthy donors was collected 
from the antecubital vein in tubes containing EDTA 
(final cont. 6 mM). After centrifugation at 200 X g 
for 15 min, the lower phase was mixed with 2% 
Dextran T-500 solution containing 0.9% of NaCI. 
After 30 min, the upper layer was gently removed 
and centrifugated at 200 X g for 15 min at O’C. 
Supernatant fluid was aspirated and erythrocytes 
were removed by hypotonic lysis (0.15 M NH&l, 
37’C for 7 min). The cell-rich solution was then frac- 
tionated on a Hypaque/Ficoll gradient [ 1 I]. After 
centrifugation at 300 X g for 40 min, the pellets were 
resuspended in phosphate-buffered saline (pH 7.4). 
Similar results were obtained using either of these 
preparations of PMNL. 
This report shows that both LTB4 and its precursor 
LTA4 cause a small rise in cyclic AMP levels which is 
greatly amplified by pretreatment with RO 20-l 724 
(an inhibitor of cyclic 3’:5’-nucleotide phosphodies- 
terase). 
2.2. Leukotrienes preparation 
Synthetic LTA, was kindly given by Dr E. J. Corey. 
LTB,, 20-OH-LTB4 and 20-COOH-LTB4 were prepared 
as in [ 12,131. LTC,, was generated biosynthetically [ 141. 
2. Materials and methods 2.3. Experimental conditions and quantitative analyses 
of cyclic AMP 
RO 20-l 724 was obtained from Hoffman La 
Abbreviations: SS-HPETE, (5S)-hydroperoxy-eicosatetraenoic 
acid; LTA,, 5,6epoxy-7,9,11,14eicosatetraenoic acid; LTB,, 
(%?I, (12R)dihydroxy6,8,10,14eicosatetraenoic acid; LTC,, 
~5~-hydroxy~6R)S-glutathionyl-7,9,11,14eicosatetraenoic 
acid; RP 20-1724,4-(3-butoxy4-methoxybenzyl)-2-imidazol- 
idinone; cyclic AMP, adenosine 3’:5’-monophosphate 
Cell suspensions (1 O-30 X 1 O6 cells/ml) were 
preincubated for 2 min at 37°C. Compounds to be 
tested were added in 1-2 ~1 ethanol to 1 ml cell sus- 
pension. Incubations were terminated by adding 
1 vol. 10% trichloroacetic acid. Cyclic AMP levels 
were determined using the protein binding technique 
in [ 15 1. Prior to analyses the samples were purified [ 16 1. 
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Fig.1. Transformation of arachidonic acid in human PMNL. 
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3. Results and discussion 
A suspension of washed human PMNL was incu- 
bated with either LT&, LTB4, or LTC+ LTA, and 
LTB4 caused asmall rise in cyclic AMP levels (table 1). 
Table 1 
Effects of LTA,, LTB, and LTC, on the levels of cyclic 
AMP in human PMNL 
Exp. Addition 
(&ml) 
Cyclic AMP 
(pmol/lO’ cells) 
1 None 22.3 f 2.4 
LTA, (300) 25.6a f 1.9 
LTB, (100) 28.1b f 1.8 
LTC, (350) 21.1n.s. f 1.1 
2 None 36.0 f. 3.9 
LTA, (100) 71.5c f 3.1 
LTB, (100) 90.0c f 1.8 
LTC, (350) 37.0ns. * 3.2 
Exp. 1: Human PMNL were incubated with either LTA,, 
LTB, or LTC, for 30 s prior to cyclic AMP analyses 
Exp. 2: Human PMNL were pretreated 2 min with RO 
20-1724 (0.1 mM). Thereafter the cells were incubated 
with either LTA,, LTB, or LTC, for 1 min 
Each value represents the mean value 2 SD from triplicate 
determination on each of 6 samples (exp. 1) or 3 samples 
(exp. 2). Statistical differences were performed using 
Student’s t-test: ap<0.05;bp<0.01;Cp<0.001;n.s., 
not significant 
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These effects were greatly amplified in the presence 
of RO 20-l 724 (an inhibitor of cyclic 3’:S’nucleotide 
phosphodiesterase, EC 3.1.4.17). Similar results were 
obtained using another phosphodiesterase inhibitor, 
3-isobutyl-1-methylxanthine ( ot shown). No effect 
on cyclic AMP synthesis was observed with LTC4 
(table 1). LT& and LTB, rapidly elevated the levels 
of cyclic AMP in human PMNL (tig.2a). A maximal 
effect was observed after 1 min. Similar timecourses 
have been reported in PMNLincubated withIV-formyl- 
methionyl-leucyl-phenylalanine (fMLP), ionophore 
A23 187, immune complex or zymosan-treated serum 
after pretreatment with prostaglandin Er [8] or a 
phosphodiesterase inhibitor [17]. Fig.2b shows that 
LTB4 and LTA4 were about equally potent as stimu- 
lators of cyclic AMP formation. The effect of LTB4 
on cyclic AMP synthesis i  in agreement with the 
earlier observations that agents which possess the abil- 
ity to induce superoxide anion (0;) production and 
secretion of azurophil granules also cause a small 
increment in cyclic AMP levels [8]. 
b 
m., 1 
01 2 10 20 100 200 
w/ml 
Fig.2. Effects of LTA, and LTB, on the levels of cyclic AMP in human PMNL: (a) Time-courses of the effects of LTA, (100 ng/ 
ml) or LTB, (100 ng/ml) on the tormation of cyclic AMP in the presence of RO 20-1724 (0.1 mM); (b) Dose-response curves 
showing the effects of LTA, and LTB, on cyclic AMP synthesis in the presence of RO 20-1724 (0.1 mM); (A) RO 20-1724; (m) 
LTA, + RO 20-1724; (0) LTB, + RO 20-1724. The cells were preincubated for 2 min with RO 20-1724 at 37°C. Thereafter the cells 
were incubated with LTA, or LTB, and analyzed for cyclic AMP content after indicated time (a) or 1 min (b). Each value repre- 
sents the mean value + SD from triplicate determination on each of 2 samples. 
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However, elevated cyclic AMP levels obtained 
after stimulation with various prostaglandins or phos- 
phodiesterase inhibitors lead to inhibition in [lo] of 
LTB,, synthesis and in [8,18] of enzyme release. Thus, 
an increment of cyclic AMP levels seems to be asso- 
ciated both with stimulation and inhibition of granu- 
locyte function. A possible xplanation for this is 
that agents which activate neutrophils increase the 
levels of cyclic AMP in certain compartments [ 91. 
LTB4 has been shown to release prostaglandins 
from guinea pig lung [ 191. Therefore, the effect of 
indomethacin and aspirin on the stimulatory action 
of LTB4 on cyclic AMP formation was investigated. 
Human PMNL were incubated with indomethacin 
(1 PM) or aspirin (22 PM) in combination with RO 
20-l 724 (0.1 mM) for 2 min prior to the addition of 
LTB4. In the absence of prostaglandin synthesis inhib- 
itors, LTB4 (100 ng/ml) increased the levels of cyclic 
AMP from 29.0 f 0.04 to 56.2 ?r 2.9 pmol/lO’ cells 
after 1 min. In the presence of indomethacin or aspirin, 
LTB4 increased the cyclic AMP content o 50.7 + 1.5 
and 55.2 + 3.1 pmol/lO’ cells, respectively, indicating 
that this effect on cyclic AMP was not mediated by 
prostaglandins. 
Omega oxidation of LTB4 leads to formation of 
20-OH-LTB4 and 20COOH-LTB4 [ 131 (fig.1). These 
compounds were less effective than LTB4 in stimulat- 
ing cyclic AMP formation. In the presence of RO 
20-1724 (0.1 mM), LTBll (100 ng/ml) elevated the 
basal level of cyclic AMP, 3 1.3 + 2.5 pmol/lO’ cells, 
to 70.3 If 6.4 pmol/lO’ cells whereas 20-OH-LTB4 
(100 ng/ml) and 20-COOH-LTB4 (100 ng/ml) increased 
the levels to 5 1 .l + 1.7 and 45.5 f. 4.5 pmol/lO’ cells, 
respectively, after 1 min incubation. 
This study suggests hat cyclic AMP is associated 
with the biological effects of LTB4 in human poly- 
morphonuclear leukocytes. We are further investigat- 
ing the relationship between cyclic AMP levels and 
degranulation i LTB4-stimulated leukocytes. 
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